BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
수요일, 9월 30

Jasper Therapeutics Inc

JSPRNASDAQ
Trade with Public
Trade with Public
$0.6070
-0.0184-2.94%
마지막 업데이트: Sep 29, 7:54 PM
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Jasper Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Jasper Therapeutics (JSPR).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

1S.Buy
6Buy
6Hold
Consensus RatingBuy# Analysts13Avg. Consensus PT$8Upside to Avg. PT+1282.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026Piper SandlerBiren AminInitiateOverweight$2
May 15, 2026TD CowenYaron WerberDowngradeBuy→Hold—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Initiates Coverage On Jasper Therapeutics with Overweight Rating, Announces Price Target of $2

Piper Sandler analyst Biren Amin initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Overweight rating and announces Price Target of $2.
Benzinga Newsdesk

Jasper Closes Kira Deal, Extends Cash Runway

Jasper Therapeutics (JSPR) acquires Kira Pharma & raises $132M, extending its cash runway into 2028. Shares surge 20%+.
Vandana Singh

PRO
TD Cowen Downgrades Jasper Therapeutics to Hold

TD Cowen analyst Yaron Werber downgrades Jasper Therapeutics (NASDAQ:JSPR) from Buy to Hold.
Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $3

RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Perform and lowers the price target from $4 to $3.
Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $7

Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the price target from $12 to $7.
Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $4

RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Perform and lowers the price target from $5 to $4.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved